SMARCAD1-DT: A Potential Cancer Treatment Target (G101929210)

Target Name: SMARCAD1-DT

NCBI ID: G101929210

SMARCAD1-DT

Other Name(s): SMARCAD1 divergent transcript

SMARCAD1-DT: A Potential Cancer Treatment Target

SMARCAD1-DT (SMARCAD1 divergent transcript) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The SMARCAD1 gene is a non-coding RNA molecule that is located on chromosome 6p21. It is a part of the SMARTCIST complex, a protein-coding gene that is involved in the regulation of stem cell growth and differentiation.

SMARCAD1-DT has been shown to play a role in the regulation of cellular processes that are important for cancer development and progression. For example, studies have shown that SMARCAD1-DT can promote the growth and survival of cancer cells, and that it is involved in the development of resistance to chemotherapy.

In addition to its role in cancer, SMARCAD1-DT has also been shown to be involved in the regulation of stem cell development and differentiation. This suggests that it may be a potential drug target for diseases that are characterized by the over-regulation of stem cells, such as neurodegenerative diseases.

One of the key challenges in studying SMARCAD1-DT is its location on chromosome 6p21. This location makes it difficult to study, as many genetic studies have been shown to be highly dependent on the position of the gene on the chromosome. However, research into SMARCAD1-DT has shown that it is expressed in a wide variety of tissues and cells, including brain, heart, and blood cells.

Another challenge in studying SMARCAD1-DT is its role in the regulation of cellular processes that are important for cancer development and progression. This makes it difficult to predict how SMARCAD1-DT might be used to treat cancer, as the underlying mechanisms that regulate its function are not well understood. However, research into SMARCAD1-DT has shown that it is involved in the regulation of several processes that are important for cancer development, including cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels).

Despite these challenges, research into SMARCAD1-DT has shown that it is a promising drug target or biomarker for the treatment of cancer. Studies have shown that SMARCAD1-DT can be overexpressed in cancer cells, and that inhibition of its function can lead to the growth inhibition and apoptosis of these cells. In addition, research has shown that SMARCAD1-DT is involved in the regulation of stem cell development and differentiation, which suggests that it may be a potential drug target for neurodegenerative diseases.

In conclusion, SMARCAD1-DT is a gene that has been identified as a potential drug target or biomarker for the treatment of cancer. Its location on chromosome 6p21 and its involvement in the regulation of cellular processes that are important for cancer development and progression make it difficult to study, but research into its function has shown that it is involved in the regulation of several important processes that are involved in cancer development. Further research is needed to understand its potential as a drug target or biomarker.

Protein Name: SMARCAD1 Divergent Transcript

The "SMARCAD1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMARCAD1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets